Download PDF
CC BY-NC-ND 4.0 · Arquivos Brasileiros de Neurocirurgia: Brazilian Neurosurgery 2022; 41(04): e375-e378
DOI: 10.1055/s-0042-1749375
Case Report

Recurrence of Anaplastic Large Cell Lymphoma in the Frontal Lobe After Eleven Years of the Initial Diagnosis: Histopathological Findings and Prognosis

Recorrência de linfoma anaplásico de grandes células no lobo frontal onze anos após o diagnóstico inicial: Achados histopatológicos e prognóstico
Eduardo Cambruzzi 
1   Medicine Faculty, Department of Histology and Pathology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil
2   Departamento de Patologia, Hospital Santa Rita, Santa Casa da Misericórdia de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
3   Grupo Hospitalar Conceição, Porto Alegre, Rio Grande do Sul, Brazil
4   Hemodynamics Department, Instituto de Cardiologia, Fundação Universitária de Cardiologia, Porto Alegre, Rio Grande do Sul, Brazil
,
Nelson Pires Ferreira 
2   Departamento de Patologia, Hospital Santa Rita, Santa Casa da Misericórdia de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
,
Marcelo Paglioli Ferreira 
2   Departamento de Patologia, Hospital Santa Rita, Santa Casa da Misericórdia de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
,
Guilherme Gago 
2   Departamento de Patologia, Hospital Santa Rita, Santa Casa da Misericórdia de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
,
João Pedro Pattussi Bertinatti 
2   Departamento de Patologia, Hospital Santa Rita, Santa Casa da Misericórdia de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
› Author Affiliations Funding Statement The authors declare that they have received no funding regarding the performance of the present study.
› Further Information
   Permissions and Reprints

Abstract

Anaplastic large cell lymphoma (ALCL) is a rare, high-grade, T-cell neoplasm classified into cutaneous primary, systemic primary ALK-positive (ALK+), systemic primary ALK-negative, or breast-implant associated. Secondary involvement of the central nervous system (CNS) by systemic primary ALK+ ALCL is a rare occurrence. We present a case of CNS involvement by ALK+ ALCL eleven years after diagnosis of the primary tumor in the thoracic vertebra. The anatomopathological examination confirmed the diagnosis of ALK+ ALCL. A brief review of the treatment and the clinical and pathological aspects is presented.

Resumo

O linfoma anaplásico de grandes células (LAGC) corresponde a uma neoplasia de alto grau rara, com imunofenótipo T, que podendo ser dividido em primário cutâneo, primário sistêmico ALK positivo (ALK+), primário sistêmico ALK negativo, e associado a próteses mamárias. Acometimento secundário do sistema nervoso central (SNC) por LAGC primário sistêmico ALK+ é uma rara entidade. Os autores apresentam um caso de acometimento do SNC por LAGC ALK+ onze anos após o diagnóstico do tumor primário em vértebra torácica. O exame anatomopatológico confirmou o diagnóstico de LAGC ALK+. Fez-se também uma breve revisão de aspectos clínicos e patológicos e tratamento.

Keywords

anaplastic large cell lymphoma - central nervous system - pathology - immunohistochemistry - prognosis

Palavras-chave

linfoma anaplásico de grandes células - sistema nervoso central - patologia - imuno-histoquímica - prognóstico


Publication History

Received: 10 June 2021

Accepted: 25 April 2022

Article published online:
05 September 2022

© 2022. Sociedade Brasileira de Neurocirurgia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 Stein H, Foss HD, Dürkop H. et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000; 96 (12) 3681-3695
    CrossrefPubMedGoogle Scholar
  • 2 Fraga M, Brousset P, Schlaifer D. et al. Bone marrow involvement in anaplastic large cell lymphoma. Immunohistochemical detection of minimal disease and its prognostic significance. Am J Clin Pathol 1995; 103 (01) 82-89
    CrossrefPubMedGoogle Scholar
  • 3 Dong X, Li J, Huo N. et al. Primary central nervous system ALK-positive anaplastic large cell lymphoma in an adult: A rare case report. Medicine (Baltimore) 2016; 95 (49) e5534
    CrossrefPubMedGoogle Scholar
  • 4 Rupani A, Modi C, Desai S, Rege J. Primary anaplastic large cell lymphoma of central nervous system–a case report. J Postgrad Med 2005; 51 (04) 326-327
    PubMedGoogle Scholar
  • 5 Vivekanandan S, Dickinson P, Bessell E, O'Connor S. An unusual case of primary anaplastic large cell central nervous system lymphoma: an 8-year success story. BMJ Case Rep 2011; 2011 DOI: 10.1136/bcr.11.2010.3550.
    CrossrefPubMedGoogle Scholar
  • 6 Feng S, Chen Q, Chen J, Zheng P, Ma K, Tan B. Primary anaplastic large cell lymphoma of the central nervous system in a child: A case report. Medicine (Baltimore) 2020; 99 (29) e21115
    CrossrefPubMedGoogle Scholar
  • 7 Fujisawa E, Shibayama H, Mitobe F, Katada F, Sato S, Fukutake T. A case of primary central nervous system anaplastic lymphoma kinase positive anaplastic large cell lymphoma manifested as a unilateral pachymeningits. Rinsho Shinkeigaku 2017; 57 (11) 705-710
    CrossrefPubMedGoogle Scholar
  • 8 Mori T, Sugita K, Kimura K. et al. Isolated central nervous system (CNS) relapse in a case of childhood systemic anaplastic large cell lymphoma without initial CNS involvement. J Pediatr Hematol Oncol 2003; 25 (12) 975-977
    CrossrefPubMedGoogle Scholar
  • 9 Wang CX, Wang H, Li J. et al. Brain metastasis of ALK positive anaplastic large cell lymphoma after a long-term disease free survival in an old adult. Int J Clin Exp Pathol 2014; 7 (03) 1182-1187
    PubMedGoogle Scholar
  • 10 Raffa EH, Branson HM, Ngan B, Alexander S, Abla O. Central nervous system relapse in a child with anaplastic large cell lymphoma: potential for new therapeutic strategies. Cancer Rep (Hoboken) 2021; 4 (05) e1377
    CrossrefPubMedGoogle Scholar
  • 11 Del Baldo G, Abbas R, Woessmann W. et al. Neuro-meningeal relapse in anaplastic large-cell lymphoma: incidence, risk factors and prognosis - a report from the European intergroup for childhood non-Hodgkin lymphoma. Br J Haematol 2021; 192 (06) 1039-1048
    CrossrefPubMedGoogle Scholar
  • 12 Pro B, Advani R, Brice P. et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30 (18) 2190-2196
    CrossrefPubMedGoogle Scholar
  • 13 Pro B, Advani R, Brice P. et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood 2017; 130 (25) 2709-2717
    CrossrefPubMedGoogle Scholar
  • 14 Fukano R, Mori T, Sekimizu M. et al. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial. Cancer Sci 2020; 111 (12) 4540-4547
    CrossrefPubMedGoogle Scholar
  • 15 Ruf S, Hebart H, Hjalgrim LL. et al. CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series. Pediatr Blood Cancer 2018; 65 (06) e27003
    CrossrefPubMedGoogle Scholar
  • 16 Abid MB, Wang S, Loi HY, Poon LM. ALK-negative anaplastic large cell lymphoma with CNS involvement needs more than just brentuximab vedotin. Ann Hematol 2016; 95 (10) 1725-1726
    CrossrefPubMedGoogle Scholar
  • 17 Central nervous system relapse of systemic ALK-rearranged anaplastic large cell lymphoma treated with alectinib
    PubMed
  • 18 Yang J, Li J, Gu WY. et al. Central nervous system relapse in a pediatric anaplastic large cell lymphoma patient with CLTC/ALK translocation treated with alectinib: A case report. World J Clin Cases 2020; 8 (09) 1685-1692
    CrossrefPubMedGoogle Scholar
  • 19 Wrona A. Management of CNS disease in ALK-positive non-small cell lung cancer: Is whole brain radiotherapy still needed?. Cancer Radiother 2019; 23 (05) 432-438
    CrossrefPubMedGoogle Scholar
  • 20 Schulte JH, Moreno L, Ziegler DS. et al. Final analysis of phase I study of ceritinib in pediatric patients with malignancies harboring activated anaplastic lymphoma kinase (ALK). Journal of Clinical Oncology 2020; 38: 10505
    CrossrefPubMedGoogle Scholar